TY - JOUR
T1 - PEGylation of Interferon-β-1a
T2 - A promising strategy in multiple sclerosis
AU - Kieseier, Bernd C.
AU - Calabresi, Peter A.
N1 - Funding Information:
Medical writing assistance was provided by Christopher Barnes and editorial support was provided by Joshua Safran, both of Infusion Communications. Their work was funded by Biogen Idec Inc. Dr Kieseier has received honoraria for lecturing, travel expenses for attending meetings and financial support for research from Baxter, Bayer Schering, Biogen Idec, Medac, Merck Serono, Novartis, Roche, Sanofi, Talecris and Teva Neuroscience. Dr Kieseier is a member of an international advisory board for the ADVANCE study, a clinical study investigating PEG-IFNb in patients with relapsing forms of MS. Dr Calabresi has received personal compensation for consulting and serving on scientific advisory boards from Biogen Idec, Teva Neuroscience, Genzyme, Vaccinex and Novartis and has received research funding from Biogen Idec, Teva, EMD Serono, Abbott, Vertex, Genentech and Bayer.
PY - 2012
Y1 - 2012
N2 - Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic properties. Numerous PEGylated therapeutics are currently available, all of which have at least comparable efficacy, safety and tolerability to their unmodified forms. A PEGylated form of interferon-β-1a (PEG-IFNβ-1a) is being developed to address an unmet medical need for safer, more effective and more convenient therapies for multiple sclerosis (MS). Phase I study data suggest that PEG-IFNβ-1a should provide patients with a first-line therapy with a more convenient dosing regimen while maintaining the established efficacy, safety and tolerability of presently available IFNβ-1a. The ongoing global ADVANCE phase III study will determine the clinical efficacy of PEG-IFNβ-1a in patients with relapsing MS.
AB - Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic properties. Numerous PEGylated therapeutics are currently available, all of which have at least comparable efficacy, safety and tolerability to their unmodified forms. A PEGylated form of interferon-β-1a (PEG-IFNβ-1a) is being developed to address an unmet medical need for safer, more effective and more convenient therapies for multiple sclerosis (MS). Phase I study data suggest that PEG-IFNβ-1a should provide patients with a first-line therapy with a more convenient dosing regimen while maintaining the established efficacy, safety and tolerability of presently available IFNβ-1a. The ongoing global ADVANCE phase III study will determine the clinical efficacy of PEG-IFNβ-1a in patients with relapsing MS.
KW - Multiple-sclerosis
KW - PEG-interferon-beta-1a.
UR - http://www.scopus.com/inward/record.url?scp=84856894168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856894168&partnerID=8YFLogxK
U2 - 10.2165/11596970-000000000-00000
DO - 10.2165/11596970-000000000-00000
M3 - Review article
C2 - 22201341
AN - SCOPUS:84856894168
SN - 1172-7047
VL - 26
SP - 205
EP - 214
JO - CNS Drugs
JF - CNS Drugs
IS - 3
ER -